CuraCloud’s AI brain software expands to chest CT

The U.S. Food and Drug Administration (FDA) is allowing medical artificial intelligence (AI) software developer CuraCloud’s new deep learning-based algorithm to be used for the detection and prioritization of incidental pneumonia findings associated with COVID-19. The findings stem from noncontrast chest CT images.

Read the full article here

Related Articles